Highlights Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.28 ^USD	+2.98%		-2.38%	+7.89%

Apr. 04	UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating	MT
Apr. 01	Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 28	MT
Sector Update: Health Care	Mar. 28	MT
Top Midday Decliners	Mar. 28	MT
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss	Mar. 28	MT
Kodiak Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Kodiak Sciences' Q3 Loss Narrows	Nov. 14	MT
Kodiak Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Kodiak Sciences Inc. Announces Phase 3 Glow Superiority Study Evaluating Tarcocimab Tedromer 5 Mg in Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy	Nov. 06	CI
Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting	Nov. 01	CI
Lonza Shares Drop After Warning of 2024 Profitability Shortfall	23-10-17	DJ
Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue	23-10-17	DJ
Lonza cuts 2024 margin target again after CEO departure	23-10-17	RE
Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study	23-09-07	CI
Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Kodiak Sciences scraps development of eye drug	23-07-24	RE
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program	23-07-24	CI
Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Kodiak Sciences Inc. Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases	23-04-03	CI
Kodiak Sciences Q4 Net Loss Narrows	23-03-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Highlights

Filters